GSK plc announced that Nucala (mepolizumab) was approved in China on January 3, 2025, for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), impacting around 30 million people. This approval offers a new non-surgical treatment option for patients inadequately controlled with existing therapies.